What does the salvage chemotherapy regimen FLAG‑IDA (Fludarabine, high‑dose Cytarabine, Granulocyte‑colony stimulating factor, Idarubicin) mean in acute myeloid leukemia?

FLAG-IDA Salvage Chemotherapy in AML

FLAG-IDA is an intensive salvage chemotherapy regimen used for relapsed or refractory acute myeloid leukemia (AML), combining fludarabine, high-dose cytarabine, granulocyte-colony stimulating factor (G-CSF), and idarubicin to achieve remission and bridge patients to allogeneic stem cell transplantation.

Regimen Components and Dosing

The FLAG-IDA protocol consists of 1:

• Fludarabine: 30 mg/m² IV on days 2-6
• Cytarabine: 1500-2000 mg/m² IV over 3 hours, starting 4 hours after fludarabine infusion, days 2-6
• Idarubicin: 10 mg/m² IV on days 2-4
• G-CSF: 5 mcg/kg subcutaneously on days 1-5, with additional G-CSF administered starting 7 days after chemotherapy completion until white blood cell count >500/μL

Dose Modifications for Older Patients

For patients >60 years, dose reductions are recommended 1:

• Fludarabine: 20 mg/m²
• Cytarabine: 500-1000 mg/m²
• Idarubicin: 8 mg/m²

Clinical Indications

FLAG-IDA is specifically indicated for 1:

1. Primary refractory AML - patients not responding to initial "7+3" induction chemotherapy
2. First relapsed AML - patients who achieved initial remission but subsequently relapsed
3. Bridge to transplantation - achieving disease control before allogeneic stem cell transplant

Efficacy Data

Real-World Outcomes

The most recent and largest real-world study analyzed 1,079 patients treated with FLAG-IDA 2:

• Complete remission composite (CRc) rate: 56.8% (CR 51.0%, CRi 4.0%)
• Median overall survival: 10.2 months
• 5-year overall survival: 21.6%
• Bridge to transplant: 35.2% of all patients, 62% of responders
• 30-day mortality: 5-9% (improved over time from 6.9% in 1998-2005 to 5.0% in 2017-2024)

Comparative Efficacy

A single-center study of 132 patients demonstrated 3:

• CR/CRi rate: 56%
• Median overall survival: 15 months
• 30-day mortality: 9%
• 60-day mortality: 16%

Prognostic Factors

The SALFLAGE prognostic score stratifies patients into three risk categories 2, 4:

Favorable Prognostic Factors:

• Prior allogeneic transplantation (HR 0.54)
• Relapse-free interval ≥1 year (HR 0.75)

Adverse Prognostic Factors:

• High-risk cytogenetics including t(8;21) (HR 3.58)
• FLT3-ITD mutation at primary diagnosis (HR 1.61)
• Age ≥60 years (HR 1.43)

Risk-Stratified Survival:

• Favorable risk (26% of patients): 52% 5-year OS
• Intermediate risk (29% of patients): 26% 5-year OS
• Poor risk (45% of patients): 7% 5-year OS

Toxicity Profile

Hematologic Toxicity

Severe myelosuppression is universal 5:

• Median neutrophil recovery: 19-29 days
• Median platelet recovery: 22-30 days
• Median hospitalization: 24-31 days

Non-Hematologic Toxicity

Common adverse effects include 3, 6, 7:

• Fever/infection: 87% (predominantly pulmonary involvement)
• Mucositis: 30-67%
• Pulmonary toxicity: 30-42%
• Transient liver toxicity: 30% (grade 2 WHO)
• Bacterial pneumonia: 39%
• Septic shock/ICU admission: 36%

Cardiac Considerations

Idarubicin carries significant cardiotoxicity risk 5:

• Monitor left ventricular ejection fraction (LVEF) before and during treatment
• Increased risk with prior anthracycline exposure, mediastinal radiation, or pre-existing cardiac disease
• Avoid concomitant cardiotoxic agents (trastuzumab, cyclophosphamide, paclitaxel)

Clinical Pitfalls and Management

Critical Monitoring Requirements

1. Hepatic/renal function: Dose reduce if bilirubin or creatinine >2 mg/dL 5
2. Cardiac function: Baseline and serial LVEF monitoring mandatory 5
3. Infection prophylaxis: Aggressive antimicrobial support required given 87% fever rate 3
4. Transfusion support: Prolonged cytopenias necessitate blood product availability

Patient Selection

This regimen should only be administered in centers with 5:

• Experienced leukemia specialists
• Intensive care capabilities
• 24/7 transfusion support
• Comprehensive infectious disease management

Contraindications

Avoid FLAG-IDA in patients with 5:

• Pre-existing severe bone marrow suppression
• Active uncontrolled infection
• Severe cardiac dysfunction (unless benefit clearly outweighs risk)
• Pregnancy (teratogenic and embryotoxic)

Strategic Role in Treatment Algorithm

FLAG-IDA serves as a bridge-to-transplant regimen rather than definitive therapy 2, 7:

1. Administer FLAG-IDA for salvage in fit patients with relapsed/refractory AML
2. Achieve morphologic remission (56.8% success rate)
3. Proceed rapidly to allogeneic stem cell transplantation (62% of responders successfully bridged)
4. Without transplantation, long-term survival remains poor despite initial response

The regimen has demonstrated improved outcomes over time, with contemporary mortality rates of 5% at 30 days compared to 6.9% historically 2, reflecting better supportive care and patient selection.